Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:
   

Hua Han Bio-Pharma and China National Biotec Announce JV

publication date: Apr 23, 2013
A subsidiary of Hua Han Bio-Pharmaceutical Holdings, Guizhou Factorr Bio-Technology Co., signed a framework agreement to set up a JV with National Vaccine & Serum Institute. NVSI is a Beijing-based company that is part of the China National Biotec Group. Guizhou will fund the JV with between 30 and 50 million RMB of capital ($5-8 million), while NVSI will contribute rights to three biopharma products. More details....

Stock Symbol: (HK: 00587)

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes


Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital